Media Contact:
Stephen Majors
Head of Global Communications
smajors@alliancerm.org
Washington, DC
Cell, gene, and tissue-based therapies are the future of medicine, with the potential to durably treat or even cure the most challenging diseases. The administration’s ‘Most Favored Nation’ Interim Final Rule could threaten innovation in regenerative medicine. If the administration is concerned about clinical outcomes and high expenditures, policymakers should embrace innovative payment models, including outcomes-based agreements that reward scientific investment when therapies work and patients’ conditions improve.
Washington, DC
Washington, DC
The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. The committee and board are subject to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.
Washington, DC
